Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41910 | 0.97 | PHGDH (0.42) | PHGDHMGLLHTR6SLC18A3MEN1 | |
| SCHEMBL7503884 | 0.97 | PHGDH (0.42) | PHGDHMGLLHTR6SLC18A3MEN1 | |
| SCHEMBL42786 | 0.97 | PHGDH (0.42) | PHGDHMGLLHTR6SLC18A3MEN1 | |
| SCHEMBL193442 | 0.94 | PHGDH (0.34) | PHGDHMGLLHTR6SLC18A3MEN1 | |
| SCHEMBL9432067 | 0.91 | PHGDH (0.38) | PHGDHMGLLHTR6SLC18A3MEN1 | |
| SCHEMBL188355 | 0.88 | — | — | |
| SCHEMBL1447602 | 0.87 | L3MBTL1 (0.34) | PHGDHMGLLHTR6SLC18A3MEN1 | |
| SCHEMBL337764 | 0.87 | L3MBTL1 (0.34) | PHGDHMGLLHTR6SLC18A3 | |
| SCHEMBL597739 | 0.84 | L3MBTL1 (0.35) | HTR6MEN1KMT2AHRH3OPRL1 | |
| SCHEMBL174054 | 0.80 | HTR6 (0.42) | PHGDHMGLLHTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | claimed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | claimed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | claimed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-115611885-A | N-substituted-5- ((4-substituted pyrimidin-2-yl) amino) -1H-indole-2-carboxamide derivatives | 厦门大学 | 2023-01-17 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-9440978-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-13 | — | — | US | claimed |
| EP-2224929-B1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-04 | — | — | EP | claimed |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-07-16 | — | — | US | claimed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | claimed |
| WO-2008064036-A1 | SUBSTITUTED PHENYL PROPYL AMINES AS HISTAMINE H3 RECEPTOR AND SEROTONIN TRANSPORTER MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-29 | — | — | WO | claimed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| US-20080004258-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | claimed |
| WO-2008002820-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| WO-2008002817-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | claimed |
| EP-1817287-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | Eli Lilly and Company (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | claimed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | claimed |
| WO-2006057845-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004258-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | PHGDH 2352/4885MGLL 3048/4885HTR6 7/4885 |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | PHGDH 2061/4885MGLL 2883/4885HTR6 6/4885 |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | TOP1, TOP2A, TOP2B | PHGDH 1056/4885MGLL 3414/4885HTR6 1540/4885 |
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | PHGDH 992/4885MGLL 1638/4885HTR6 2041/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | PHGDH 830/4885MGLL 4158/4885HTR6 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.